Видео ютуба по тегу Gvhd Hub

Symposium | Quality of life and symptoms in cGvHD
Symposium | Quality of life and symptoms in cGvHD
What are the treatment options for ruxolitinib-refractory acute GvHD?
What are the treatment options for ruxolitinib-refractory acute GvHD?
Symposium | Early treatment strategies for SR-GvHD
Symposium | Early treatment strategies for SR-GvHD
Symposium | The importance of real-world data in allogeneic cell transplantation: A focus on cGvHD
Symposium | The importance of real-world data in allogeneic cell transplantation: A focus on cGvHD
What are the current treatment options for steroid-refractory chronic GvHD?
What are the current treatment options for steroid-refractory chronic GvHD?
What are the major challenges in the treatment of SR-GvHD, and how can clinicians overcome these?
What are the major challenges in the treatment of SR-GvHD, and how can clinicians overcome these?
How can measurement of QoL and use of PROs be improved in cGvHD?
How can measurement of QoL and use of PROs be improved in cGvHD?
ECP + ruxolitinib to prevent cGvHD in patients with SR-aGvHD
ECP + ruxolitinib to prevent cGvHD in patients with SR-aGvHD
Key insights into MSCs for aGvHD – the current clinical trial landscape
Key insights into MSCs for aGvHD – the current clinical trial landscape
Real-world use of belumosudil: Key insights and future perspectives
Real-world use of belumosudil: Key insights and future perspectives
How does real-world evidence complement RCTs, and why is it important for small patient populations?
How does real-world evidence complement RCTs, and why is it important for small patient populations?
cGvHD: Answering the unanswered
cGvHD: Answering the unanswered
How should we be measuring GvHD QoL in clinical practice?
How should we be measuring GvHD QoL in clinical practice?
Results from the phase II STARGAZE trial
Results from the phase II STARGAZE trial
cGvHD symposium highlights
cGvHD symposium highlights
Infection prophylaxis for patients with GvHD
Infection prophylaxis for patients with GvHD
Management of drug related adverse events in patients with steroid refractory GvHD
Management of drug related adverse events in patients with steroid refractory GvHD
Future perspectives of ECP for GvHD treatment
Future perspectives of ECP for GvHD treatment
Symposium | Early intervention and use of ECP combinations in cGvHD
Symposium | Early intervention and use of ECP combinations in cGvHD
Symposium | Q&A | Donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops
Symposium | Q&A | Donor lymphocyte infusion post-transplant, and treatment routes if GvHD develops
Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up
Symposium | ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up
Symposium | The Long-term burden of chronic GvHD
Symposium | The Long-term burden of chronic GvHD
Symposium: A brief history of ECP
Symposium: A brief history of ECP
Symposium | Q&A | Impact of ECP on the GvHD treatment landscape
Symposium | Q&A | Impact of ECP on the GvHD treatment landscape
Supportive care provision for patients with GvHD
Supportive care provision for patients with GvHD